View Clinical Trial (Medical Research Study)
Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea - NCT00823901-94305(Clinical Trial 264190)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Stanford |
|
State:
|
|
CA |
| Zip Code: |
|
94305 |
| Conditions: |
|
Rosacea |
| Purpose: |
|
The purpose of this study is to determine whether Clindamycin Phosphate 1.2% And Tretinoin
0.025% Gel are effective and safe in the treatment of papulopustular rosacea.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
1. Subjects 18 years of age and older.
2. Clinical diagnosis of papulopustular facial rosacea.
3. A minimum of 4 but not more than 50 facial inflammatory lesions (papules plus
pustules).
4. Willing and able to understand and sign informed consent.
5. Able to complete study and comply with study procedures.
Exclusion Criteria:
1. Acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.),
or severe acne requiring systemic treatment.
2. History or presence of regional enteritis or inflammatory bowel disease (e.g.,
ulcerative colitis, pseudomembranous colitis, chronic diarrhea, or a history of
antibiotic-associated colitis, bloody diarrhea) or similar symptoms.
3. Use of topical rosacea treatments in the past 2 weeks.
4. Use of systemic antibiotics in the past 4 weeks.
5. Use of systemic retinoids within the past 3 months.
6. Use of laser or light based rosacea treatments within the past 2 months.
7. Concomitant use of medications that are reported to exacerbate rosacea, such as
topical and systemic steroids as these may impact assessments.
8. Current drug or alcohol abuse.
9. Other dermatologic conditions that require the use of interfering topical or systemic
therapy or that might interfere with study assessments such as, but not limited to,
atopic dermatitis, perioral dermatitis or acne vulgaris.
10. Clinically significant abnormal findings or conditions (other than rosacea), which
might, in the opinion of the Investigator, interfere with study evaluations or pose a
risk to subject safety during the study.
11. Subjects who are pregnant or planning a pregnancy.
12. Use of any investigational therapy within the past 4 weeks.
13. Known hypersensitivity or previous allergic reaction to clindamycin or retinoids |
|
|
|
| Study is available at: |
|
Department of Dermatology - Stanford School of Medicine
Stanford, CA 94305
United States
Primary Contact:
Emily S Gorell
Email: egorell@stanford.edu
Phone: 650-725-4302 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 22, 2011 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|